ArticleBiomedicines2022

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC).

Evangelia Pantazaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.